Biocompatibles’ Drug-Eluting UFE Treatment Would Be Marketed By Terumo
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles International may await development of a drug-eluting version of its Bead Block microspheres therapy before seeking FDA clearance for uterine fibroid embolization (UFE)